...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?
【24h】

Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?

机译:高档骨肉瘤的遗传检测:未来定制治疗的指南?

获取原文
获取原文并翻译 | 示例

摘要

Introduction: Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered: This review provides an overview of the state of art in genetic testing applied to osteosarcoma, with particular regard to novel candidate genetic biomarkers that can be analyzed in tumor tissue and blood samples, which might be used to predict toxicity and prognosis, detect disease relapse, and improve patients' selection criteria for tailoring treatment.Expert commentary: Genetic testing based on modern technologies is expected to indicate new osteosarcoma-related prognostic markers and driver genes, which may highlight novel therapeutic targets and patients stratification biomarkers. The definition of tailored or targeted treatment approaches may improve outcome of patients with localized tumors and, even more, of those with metastatic disease, for whom progress in cure probability is highly warranted.
机译:介绍:由于常规和新候选驱动和基因组技术的综合应用,骨肉瘤的遗传表征在过去十年中已经进化。涵盖地区:本综述概述了应用于骨肉瘤的遗传检测中的最新技术,特别方面是可以在肿瘤组织和血液样本中分析的新型候选遗传生物标志物,这些生物标志物可用于预测毒性和预后,检测疾病复发,改善患者的剪裁治疗审查标准。预计基于现代技术的基因检测有望表示新的骨肉瘤相关预后标志物和驾驶员基因,这可能突出新的治疗靶标和患者分层生物标志物。定制或有针对性的处理方法的定义可以改善局部肿瘤患者的结果,以及甚至更多的具有转移性疾病的患者,其治疗概率的进展是高度保证的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号